Investigating the efficacy of mineralocorticoid receptor antagonists for cardiovascular outcomes in different diseases

Investigating the efficacy of mineralocorticoid receptor antagonists for cardiovascular outcomes in different diseases

Abstract Aims Mineralocorticoid receptor antagonists (MRAs) are crucial in managing cardiovascular diseases, with different MRAs demonstrating varying efficacy across diverse disease contexts. This research aims to compare the cardiovascular protective effects of different MRAs across various diseas...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jiao Wang, Meijuan Zheng, Yuchun Yang, Lei Zhang, Muhuyati Wulasihan
Format:	Article
Language:	English
Published:	Wiley 2025-08-01
Series:	ESC Heart Failure
Subjects:	Cardiovascular MACE Mineralocorticoid receptor antagonist MRA Original research
Online Access:	https://doi.org/10.1002/ehf2.15329
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cardiovascular-Kidney-Metabolic Effects: Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists
by: Biykem Bozkurt, et al.
Published: (2025-07-01)

Paradigm shift on the role of mineralocorticoid receptor antagonists in hypertension therapy
by: S. R. Gilyarevsky, et al.
Published: (2023-10-01)

Aldosterone-Related Cardiovascular Disease and Benefits of Mineralocorticoid Receptor Antagonists in Clinical Practice
by: Maria Alfarano, MD, PhD, et al.
Published: (2025-06-01)

Adrenal venous sampling outcomes with and without mineralocorticoid receptor antagonists in primary aldosteronism
by: Sittikul Thipbumrung, et al.
Published: (2025-07-01)

Efficacy and safety of mineralocorticoid receptor antagonists in kidney transplant patients: an updated meta-analysis of randomized controlled trials
by: Paula Dibo, et al.
Published: (2025-08-01)

PATIENT WITH CHRONIC HEART FAILURE. RATIONAL CHOICE OF THERAPY
by: O. M. Drapkina, et al.
Published: (2017-09-01)

ANGIOTENSIN II RECEPTOR ANTAGONISTS AND ACE INHIBITORS: OPTIMIZATION OF CHOICE FOR TREATMENT OF CARDIOVASCULAR DISEASES
by: E. M. Khurs, et al.
Published: (2016-01-01)

Prospects of finerenone use in Russian population of patients with chronic kidney disease and type 2 diabetes. Resolution of multidisciplinary. Advisory board
by: M. V. Shestakova, et al.
Published: (2023-11-01)

Novel cardioprotective and nephroprotective combination in patients with type 2 diabetes and chronic kidney disease: perspectives of use
by: Yu. Sh. Khalimov, et al.
Published: (2024-03-01)

Angiotensin II type 1 receptor antagonists and their combinations in the treatment of hypertension
by: J.A. Ker
Published: (2012-06-01)

Calcium antagonists in patients with high cardiovascular risk
by: A. A. Garganeeva
Published: (2009-08-01)

EXPERIENCE OF USING THE NONSELECTIVE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
by: M. A. Simakova, et al.
Published: (2018-04-01)

EXPRESSION OF PATTERN-RECOGNIZING RECEPTORS AND TRANSCRIPTIONAL REGULATORS OF T HELPER CELL DIFFERENTIATION BY INTESTINAL LYMPHOCYTES IN EXPERIMENTAL ILEITIS AND UPON ADMINISTRATION OF SIMVASTATIN AND INTERLEUKIN-1 RECEPTOR ANTAGONIST
by: A. S. Zherebiatiev, et al.
Published: (2015-04-01)

PLACE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN ARTERIAL HYPERTENSION THERAPY
by: S. A. Boytsov, et al.
Published: (2016-01-01)

The importance of co-receptors in antiretroviral therapy and novel studies on non-peptide, small molecule chemokine receptor type 5 (CCR5) antagonists
by: Dilek Aksoy, et al.
Published: (2025-05-01)

A TWO-YEAR STUDY OF CANCEROGENIC POTENTIAL OF THE NEW OPIOID RECEPTOR ANTAGONIST ONDELOPRAN IN RATS
by: K. L. Kryshen, et al.
Published: (2019-06-01)

Population Pharmacokinetic Modeling of the Oral Calcitonin Gene‐Related Peptide Receptor Antagonist Rimegepant in Adults
by: Craig M. Comisar, et al.
Published: (2025-08-01)

Effect of levothyroxine on major adverse cardiovascular events in patients with hypothyroidism and cardiovascular disease
by: Lijia Liu, et al.
Published: (2025-08-01)

ALDOSTERONE AND OBESITY: WHERE TO LOOK FOR THE KEY TO THERAPY?
by: N. T. Vatutin, et al.
Published: (2016-08-01)

Endothelial functional activity and circadian blood pressure dynamics in hypertensive patients treated with angiotensin receptor antagonists
by: N. G. Poteshkina, et al.
Published: (2011-10-01)

OPPORTUNITIES FOR OPTIMIZATION OF DRUG THERAPY BY ENDOTHELIN RECEPTOR ANTAGONISTS FOR THE PATIENT WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION AND ATRIAL SEPTOSTOMY
by: V. V. Gramovich, et al.
Published: (2018-12-01)

Baxdrostat and finerenone: new aldosterone synthase-aldosterone-mineralocorticoid receptor hormonal system inhibitors for the drug treatment of resistant arterial hypertension
by: O. B. Kuzmin, et al.
Published: (2024-10-01)

A SELECTIVE ANTAGONIST OF MINERALOCORTICOID RECEPTOR EPLERENONE IN CARDIOLOGY PRACTICE
by: B. B. Gegenava, et al.
Published: (2015-09-01)

Stroke in the Young: A Case of CNS Vasculitis Secondary to Systemic Lupus Erythematosus
by: John Badir, et al.
Published: (2025-07-01)

Evaluation of Four Semi‐Mechanistic Models for Predicting Glycemic Control With a Glucagon Receptor Antagonist in People With Type 2 Diabetes
by: Austin Yue Feng Tan, et al.
Published: (2025-08-01)

Intellectual Capital and Chaos of Innovation: Antagonist Coalition in Organizations
by: Asiye Yüksel
Published: (2023-06-01)

Hipoadrenocorticismo em cães
by: Luiza Mendes de Souza, et al.
Published: (2024-09-01)

PROSPECTS OF Toll-LIKE RECEPTOR AGONISTS AND ANTAGONISTS FOR PREVENTION AND TREATMENT OF VIRAL INFECTIONS
by: A. A. Nikonova, et al.
Published: (2019-07-01)

Safety, Tolerability, and Pharmacokinetics of Filapixant, a Highly Selective P2X3 Receptor Antagonist, in an Ascending-Single-Dose First-in-Human Study
by: Klaus Francke, et al.
Published: (2025-05-01)

APPLICATION OF CALCIUM ANTAGONISTS IN PREVENTION OF CARDIOVASCULAR COMPLICATIONS DURING CARDIAC SURGERY
by: S. V. Nedogoda
Published: (2016-01-01)

Comparative cardiovascular outcomes and safety of hypoglycemic drug classes in patients with type 2 diabetes and hypertension: a multicenter cohort analysis
by: Zhiyuan Wei, et al.
Published: (2025-08-01)

Pyridyl-Ala in the third position of radiolabeled somatostatin antagonists: the effect of regioisomeric substitution
by: Rosalba Mansi, et al.
Published: (2025-07-01)

Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2− advanced or metastatic breast cancer: phase 1/2 study results
by: Erika P. Hamilton, et al.
Published: (2025-07-01)

Cardiac scoring systems, coronary artery disease and major adverse cardiovascular events: A scoping review
by: Preesha Premsagar, et al.
Published: (2023-08-01)

DIHYDROPYRIDINE CALCIUM ANTAGONISTS: DATA OF EVIDENCE BASED MEDICINE AND RECOM-MENDATIONS ON PRACTICAL USE
by: S. Y. Martsevich
Published: (2015-12-01)

DIHYDROPYRIDINE CALCIUM ANTAGONISTS: THE ROLE IN CURRENT THERAPY OF CARDIO-VASCULAR DISEASES
by: E. V. Shilova, et al.
Published: (2016-01-01)

Interleukin-1 receptor antagonist overexpression in mesenchymal stem cells improves hemorrhagic cystitis outcomes via HtrA serine peptidase 3
by: Jialin Song, et al.
Published: (2025-07-01)

Trimethylamine-N-oxide (TMAO) and risk of incident cardiovascular events in the multi ethnic study of Atherosclerosis
by: Matthew J. Budoff, et al.
Published: (2025-07-01)

Insight mechanism of ANN model for denitrification in spouted bed bioreactor
by: Keshava Joshi, et al.
Published: (2025-07-01)

Improving Cerebrovascular Imaging with Deep Learning: Semantic Segmentation for Time-of-Flight Magnetic Resonance Angiography Maximum Intensity Projection Image Enhancement
by: Tomonari Yamada, et al.
Published: (2025-03-01)